VESTECK SAB Member Accepts International Leadership Appointment
01 May 2023
Executive ChangeAHA
WEST CHESTER, Pa., May 1, 2023 /PRNewswire/ -- VESTECK, Inc. is pleased to announce, Scientific Advisory Board member Dr. Dai Yamanouchi has accepted the role of Professor and Chairman of the Department of Vascular Surgery at Fujita Health University, Toyoake City, Japan. Fujita Health University encompasses four hospital campuses.
Professor Yamanouchi is also currently an Associate Professor at the Univ. of Wisconsin School of Medicine.
Continue Reading
Prof. Yamanouchi, "durability is a challenge for EVAR/TEVAR patients globally."
Tweet this
Among his other notable accomplishments, Professor Yamanouchi teamed with Professor Dainis Krievins to successfully complete the first two clinical cases ever performed using the VESTECK, Inc. "SUTURE-TIGHT"™ catheter in Riga, Latvia. There are now 5 successful "SUTURE-TIGHT"™ clinical cases completed.
After his initial implants, Prof. Yamanouchi commented, "the "SUTURE-TIGHT"™ device is a game-changer in the endovascular repair of aortic aneurysms. With its ability to secure stent grafts to the aortic wall, it addresses a critical unmet clinical need." Prof. Yamanouchi stressed, "durability is a significant global challenge for EVAR/TEVAR patients and I look forward to working with VESTECK, Inc. to bring the "SUTURE-TIGHT"™ catheter to Japan."
About Vesteck Inc.
VESTECK, Inc. (WWW.VESTECK.com) is a clinical stage medical device company focused on bringing a proprietary technology to the endovascular aortic repair and structural heart markets. The "SUTURE-TIGHT"™ nitinol suture delivery catheter, is easy to use, it simply and safely sutures endovascular grafts to the aorta at the initial implant or during repair procedures.
The VESTECK, Inc. "SUTURE-TIGHT"™ is not commercially available in the USA or outside the USA.
VESTECK, Inc recently announced it is raising a $16M Series B round to support a clinical trial for FDA 510K clearance.
MEDIA CONTACTS: VESTECK, Inc. CEO, Joe Rafferty, [email protected] 610-457-7324
Please note that this document reflects comments that may constitute forward-looking statements and projections that are subject to risks and uncertainties, including information about possible or assumed future events, results of economic conditions and VESTECK's business, results of operations, plans and objectives. These statements are based on management's beliefs, assumptions and expectations of VESTECK's future performance, taking into account information currently available to it. You should not place undue reliance on such statements, as new risks and uncertainties may arise and it is not possible for management to predict those events or how they may affect VESTECK, Inc.
SOURCE VESTECK, Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.